Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to determine best disease response to treatment with CAMPATH administered subcutaneously (SC) for up to 18 weeks in patients with B-Cell Chronic Lymphocytic Leukemia (B CLL) who have been previously treated.
Critère d'inclusion
- B-cell Chronic Lymphocytic Leukemia